Jeff Heiser is the Chief Scientific Officer (CSO) of Microbial and Advanced Therapeutic Platforms at Boston Analytical. After graduating from the University of New Hampshire with a degree in Microbiology Research in 2007, he entered the industry working for Pfizer Biologics at their site in Andover, MA. There he worked on rapid Microbiological methods for multivalent vaccines and biologic products.
Following Pfizer, Jeff joined Genzyme Biosurgery in direct support of autologous knee cartilage and skin graft products. In 2012, Jeff joined Boston Analytical where he worked his way to becoming the Director of Microbiology, growing the lab in support of release testing and environmental monitoring. In 2020, Jeff joined Arranta Bio, a CDMO, leading their Analytical Development and Process Science efforts in Live Biotherapeutic Products (LBP), Plasmid DNA (pDNA), and mRNA modalities.
In 2023 Jeff rejoined the Boston Analytical team as the Chief Scientific Officer (CSO) to lead the scientific thought leadership initiatives on Microbiological and advanced therapeutic platforms. Advanced therapeutics included not only LBP, but also Plasmid DNA, mRNA, and Gene Therapy modalities. Jeff’s primary focus in the coming months will be to advance our Microbiome expertise and to roll out a comprehensive analytical solution for our mRNA platform clients.
With Jeff’s extensive industry experience in the microbiology space and beyond he is a great addition to our company as CSO. Jeff will lead research and development efforts, ensuring that our services continue to be innovative and effective in meeting our customers’ needs. We are confident that Jeff will make significant contributions to our company’s growth and success!
For interest in the many testing services that Boston Analytical offers, click here